版本:
中国

BRIEF-Aptevo Therapeutics presents clinical data on safety and efficacy of Ixinity in children with Hemophilia B

April 10 Aptevo Therapeutics Inc

* Aptevo Therapeutics presents new clinical data evaluating the safety and efficacy of Ixinity in children with Hemophilia B

* Aptevo Therapeutics Inc - data suggest that Ixinity appears to be safe and well tolerated in the subject population

* Aptevo Therapeutics Inc - new data is comparable to results from overall patient population studied in pivotal clinical trial of Ixinity

* Aptevo Therapeutics - Adverse events in study believed to be related to Ixinity were hyperhidrosis, fever in one patient, hyperhidrosis in another patient

* Aptevo Therapeutics - "Look forward to building on data set in a pediatric setting to support a label expansion for ixinity in patients under 12 years of age" Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐